Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s Generic Bupropion XL Meets Bioequivalence To Wellbutrin XL, FDA Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

Reported loss of antidepressant effect likely owed to natural disease progression, agency says.
Advertisement

Related Content

Generic Bupropion XL Must Be Retested; Teva/Impax 300 mg Withdrawn After Efficacy Concerns
FDA’s Latest PR Push: Protecting the Reputation of Generic Drugs
Wellbutrin XL Generic From IntelGenx/Cary Pharma Delayed By Manufacturing, Food Effect Concerns
Wellbutrin XL Generic From IntelGenx/Cary Pharma Delayed By Manufacturing, Food Effect Concerns
Wellbutrin XL Generic Needs Longer Study To Assess Switch Issues, Biovail Asserts
FDA Aims To Bolster Generics' Image With Research, Regulatory Changes
FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
Valeant Wins Stay On Efudex Generic
Teva's Generic Wellbutrin XL For Major Depressive Disorder Launches
Teva's Generic Wellbutrin XL For Major Depressive Disorder Launches

Topics

Advertisement
UsernamePublicRestriction

Register

PS067590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel